Background. The staphylococcal surface polysaccharide poly N-acetyl glucosamine (PNAG) is a target for killing and protective antibody in animals. We investigated the human antibody response and specificit of binding and opsonic antibodies for different epitopes on PNAG in serum samples from patients with cystic fib osis (CF) colonized and not colonized with Staphylococcus aureus.
a b-1-6-linked polymer of N-acetyl glucosamine (PNAG), which has a high level (80%-100%) of the amino groups substituted with acetates [5, 6] . PNAG is also referred to as the capsular polysaccharide adhesin of S. epidermidis and the polysaccharide intercellular adhesin of S. epidermidis and S. aureus. PNAG is synthesized by proteins encoded by the ica locus found in nearly all S. aureus strains and a large number of S. epidermidis clinical isolates [7] [8] [9] [10] .
Previous studies have shown that rabbits and mice immunized with purifie PNAG elicit specifi opsonic killing antibodies to both S. aureus and S. epidermidis. In addition, mice immunized with purifie PNAG were protected against S. aureus challenge in a kidney infection model [11] , and rabbits immunized with PNAG (referred to as capsular polysaccharide adhesin) were protected against catheter-related bacteremia and endocarditis caused by S. epidermidis [12] . However, little is known about the epitope specificit of the opsonic protective antibodies, particularly in the context of the human immune response to PNAG. Because prior work has shown that sputum samples and lung tissues taken from patients with cystic fib osis (CF) colonized with S. aureuscontain PNAG-elaborating strains [11] , it was hypothesized the serum samples from these patients could be investigated to defin the epitopic specificit of antibodies to PNAG. Therefore, in the present study, we examined the opsonic killing activity in serum samples from patients with CF of antibodies directed at the deacetylated (backbone) and acetylated epitopes of PNAG, using both whole serum and affin ity-purifie antibody populations directed at the epitopes in question. We found that human antibodies to the deacetylated epitopes on PNAG were superior at eliciting in vitro opsonic killing, a clear correlate of protective activity of antibodies to gram-positive pathogens.
MATERIALS AND METHODS
Serum samples from patients with CF. Samples were obtained after written, informed consent had been obtained and as approved by the institutional review board of Children's Hospital, Boston. Clinical and demographic data describing patients included are presented in table 1. Colonized patients were define as having 3 consecutive positive results for S. aureus from culture of oropharyngeal specimens obtained at least 1 month apart during the year before serum samples were obtained. Patients not colonized with S. aureus were define as having no positive culture results for this organism during the year before serum samples were obtained, with at least 3 cultures available for review. Serum samples from a total of 31 patients (16 colonized with S. aureus and 15 noncolonized) were collected from subjects with an age range of 1-30 years. Approximately 5 serum samples were collected for each of the following age ranges for both colonized and noncolonized patients: 1-10, 11-20, and 20-30 years.
Purificatio and chemical modificatio of PNAG. The purificatio of PNAG was done as described elsewhere [5] . To remove 180% of the N-and O-linked substituents from native PNAG, purifie PNAG was dissolved at 0.5 mg/mL in 5 mol/ L NaOH and incubated for 18 h at 37ЊC with stirring. The solution was neutralized to a fina pH between 6 and 8, dialyzed against deionized water for 24 h, and freeze dried.
Quantitation of PNAG-and deacetylated PNAG (dPNAG)-specifi IgG. A previously described [5] ELISA protocol was used, with modification to quantify antibody. These included use of Immulon 4 HBX microtiter plates (Thermo LabSystems) coated with 100 mL of a previously determined optimal binding concentration of each antigen (0.6 mg/mL for native PNAG or 3 mg/mL for dPNAG) dissolved in sensitizing buffer (40 mmol/ L phosphate buffer) and incubated overnight at 4ЊC. Plates were washed 3 times with PBS that contained 0.05% Tween 20 (washing buffer) and were blocked with 200 mL of 5% skim milk dissolved in PBS. Plates were then incubated overnight again at 4ЊC. Addition of primary and secondary antibodies was as described elsewhere [5] . To quantify PNAG-or dPNAG-specifi IgG, a standard curve was generated in the assay, using known concentrations of a protein G-purifie human IgG1 monoclonal antibody, F598, which binds to both PNAG and dPNAG [13] . The concentration of purifie monoclonal antibody F598 was determined by measurement of the optical density at 280 nm. For the standard curve, we plotted nanograms per milliliter of monoclonal antibody versus the optical density at 405 nm and determined the formula for the best-fi line over the linear portion of the curve, using the least-squares method.
Quantificatio of PNAG-and dPNAG-specifi IgM. PNAGand dPNAG-specifi IgM were quantifie using a protocol sim- Figure 1 . Opsonophagocytic activity to Staphylococcus aureus in serum samples from patients with cystic fibrosis colonized and not colonized with S. aureus. Serum samples were used at a 1:10 dilution and adsorbed for 1 h with the Dica strain of S. aureus Mn8 to remove non-poly Nacetyl glucosamine-specific antibody before being added into the assay. Opsonophagocytic killing activity of colonized patients was significantly different from that of noncolonized patients ( , t test). P ! .0001 ilar to the IgG quantificatio described above, with the following modifications To generate the standard curve, 2 rows of the microtiter plate were coated with 100 mL of a solution of 0.6 mg of anti-human IgM/mL (Sigma). Human IgM (Sigma) was then added to these wells, and alkaline phosphatase-conjugated anti-human IgM (Sigma; 1:1000 dilution) was used as the secondary antibody for the standard curve and to detect IgM antibodies binding to PNAG-or dPNAG-coated wells.
Competition ELISA. To determine the specificit of antibodies to acetylated epitopes on native PNAG or backbone epitopes on dPNAG, ELISA plates were sensitized with these antigens and blocked as described above. Serum samples to be analyzed were diluted to a concentration twice that which would result in OD 405 readings of ∼1.0. Dilutions of the competing antigens (PNAG or dPNAG) were then mixed with an equal volume of the diluted serum samples, and this mixture was added to the antigen-coated and blocked wells. The remainder of the ELISA continued as described above, although no standard curve was included.
Opsonophagocytic assays. The phagocyte-dependent opsonic killing assay was done as described elsewhere [5] . To make the assay specifi to the PNAG molecule, patients' serum samples diluted 1:10 were adsorbed with 10 9 cfu/mL for 1 h at 4ЊC with S. aureus strain MN8Dica [14] , which cannot synthesize the PNAG antigen. To determine bacterial killing, 4 components of 100 mL each of diluted, adsorbed serum or purifie antibody; 7.5% infant rabbit serum as a complement source; peripheral blood leukocytes from various human do- 6 3 ϫ 10 nors; and cfu of S. aureus strain Mn8 [15] as the target 5 3 ϫ 10 organism were mixed for 90 min at 37ЊC. Surviving bacteria were quantifie by dilution and plating. No bacterial killing was observed if any of the 3 immune effector components were left out of the assay.
Affinit purificatio of antibody. Affinit columns were made by covalently attaching purifie PNAG or dPNAG to cyanogen bromide-activated Sepharose Fast Flow (Amersham Pharmacia), in accordance with the manufacturer's instructions. To separate the dPNAG-specifi antibodies from the specifi antibodies that bind to acetylated PNAG, serum samples were firs dialyzed into 20 mmol/L phosphate buffer (pH 7.0), filte sterilized, and loaded onto a column with immobilized dPNAG equilibrated in 20 mmol/L phosphate buffer. After extensive washing to remove unbound antibodies, which were collected for later recovery of native PNAG-specifi antibody, the dPNAG-bound antibodies were eluted with 0.1 mol/L glycine buffer (pH 2.6) into tubes that contained a volume of 1.0 mol/L Tris-HCl (pH 9.0) sufficien to immediately neutralize the eluate, after which fractions were pooled and dialyzed overnight into PBS (pH 7.2). The affinity-purifi antibodies were concentrated and then analyzed in ELISA and opsonophagocytic assay. The flow-th ough from the dPNAG column was then added to the PNAG column, and, after extensive washing, antibodies binding to the acetate-dependent determinants on PNAG were eluted in 0.1 mol/L glycine and recovered as described above. ELISA using PNAG and dPNAG as coating antigens was used to monitor the success of the affinit purification and to test the epitope specificit of the recovered affinity-purifi antibodies. Affinity-purifi antibodies were then quantifie with anti-human IgG (Sigma)-coated ELISA plates, a human IgG standard (Sigma), and secondary antibody, using the ELISA methods described above.
Statistical analysis. Two-group comparisons were made by an unpaired t test. Curve fittin and regression analysis used the Prism software package (version 3.0; GraphPad).
RESULTS
Opsonophagocytic activity of patient serum. We initially tested the ability to mediate PNAG-specifi antibody-and complement-dependent opsonophagocytic killing of S. aureus strain Mn8 of 16 serum samples from colonized patients with CF from 15 noncolonized patients. Figure 1 shows that patients colonized with S. aureus had significantl higher PNAG-specifi opsonophagocytic killing activity than did noncolonized patients ( , t test). A broad range of opsonophagocyt-P ! .0001 ic killing activity was also evident in the colonized patients' serum samples. We generally found that the serum samples from the colonized patients with the lowest activity were from the youngest patients (р2 years old), which may reflec a shorter exposure period or a reduced ability to mount an antibody response to this bacterial carbohydrate antigen in younger patients with CF. Epitope specificit of the human antibody response to PNAG during S. aureus infection. Because we observed that the noncolonized patients with CF had very low PNAG-specifi opsonophagocytic activity against S. aureus and because of the range of killing activity in serum samples from the colonized patients, we examined in more detail at the epitope specificit of the antibody response of these patients to both PNAG and dPNAG. The levels of IgG specifi to PNAG and dPNAG, as well as IgM specifi to PNAG, were quantifie in an ELISA. Table 2 shows that there were no significan differences in either IgM or IgG responses in either group to either the acetate-specifi or backbone (deacetylated)-specifi epitopes in patients with CF. We also noted a large range of antibody concentrations present in serum samples from both patient groups, as indicated by the SDs. The response to PNAG and dPNAG in both patient populations was overwhelmingly IgG2, with only a small amount (!15%) of an IgG1 response detected (data not shown). Overall, simple quantificatio of antibody to either PNAG or dPNAG failed to differentiate serum samples with PNAG-specifi opsonic killing from serum samples lacking such activity.
We next determined whether antibody to a define glycoform of the PNAG antigen would show a relationship with the level of opsonic killing measured in serum samples from colonized patients. As is seen in figu e 2A, levels of PNAGspecifi IgG correlated modestly with opsonophagocytic killing activity (R p 0.761, sigmoidal regression), and PNAGspecifi IgM levels (data not shown) correlated poorly (R p 0.15, linear regression;
). dPNAG-specifi IgG levels P p .66 correlated better with opsonophagocytic activity ( , R p 0.927 sigmoidal regression) (figu e 2B). These results indicate that, when opsonic killing activity is present, the antibodies directed to the backbone of PNAG are more functional at phagocyte-dependent killing than are antibodies directed at the acetate-dependent epitopes.
To understand better the characteristics of the populations of antibodies that may be present in the serum samples from these patients, competition ELISAs were performed using both the native and deacetylated forms of the antigen as the coating and competing antigens. Figure 3A shows the average of the results from 6 serum samples, which indicate that the native form of PNAG was better able than dPNAG to inhibit the binding of human antibody to an ELISA plate coated with the respective antigen. This result indicates that there are some unshared epitope(s) between PNAG and dPNAG. However, when dPNAG was used to coat an ELISA plate (figu e 3B), both PNAG and dPNAG comparably inhibited the binding of antibodies to dPNAG. This result shows that all of the epitopes on dPNAG are also expressed on the native PNAG and that the acetate-specifi groups do not block the binding of antibodies directed at the backbone of the PNAG antigen.
Opsonic killing activity of affinity-purifi antibodies. PNAG-and dPNAG-specifi antibodies were affinit purifie using cyanogen bromide-activated Sepharose to which these 2 antigens had been covalently linked. Because PNAG binds antibodies specifi to both the acetylated and nonacetylated epitopes, serum samples were firs allowed to bind to the dPNAG column to recover the antibodies specifi to these epitopes. The flow-th ough from the dPNAG column contained antibodies specifi to acetylated PNAG that were then affinit purifie by use of the PNAG column. ELISAs confi med that the dPNAGspecifi affinity-purifi antibodies bound well to both native PNAG and dPNAG, whereas the PNAG-specifi antibodies bound only to the acetylated PNAG antigen and not to dPNAG (data not shown). The 2 isolated antibody preparations were then analyzed for killing activity in the opsonophagocytic assay, and all samples were run in the same assay whenever possible, to keep variability to a minimum. Ten serum samples from the colonized patients, including those presented in figu e 3, were used to isolate dPNAG-and acetate-specifi antibody populations. As expected, for 9 of the 10 serum samples, the opsonophagocytic activity was enriched 30-100-fold when the IgG level was correlated to opsonic killing level. Results in the opsonic killing assay for 3 of these 10 serum samples are shown in figu e 4. It is clear from this result that antibodies directed at the backbone of PNAG are major mediators of the opsonophagocytic killing of S. aureus.
We were able to successfully purify populations of antibodies specifi to either dPNAG or native PNAG from the serum samples from 8 colonized patients. When we compared the opsonic killing activity of the affinity-purifi backbone-specifi antibodies with that of the affinity-purifi acetate-specifi antibodies, we found a clear superiority in opsonic killing mediated by the backbone-specifi antibodies, compared with the acetate-specifi antibodies isolated from the same serum, for 5 of the serum samples (figu e 5; samples CF9, CF4, CF13, CF16, and CF17). Interestingly, with 2 of the other 3 serum samples (figu e 5; CF3 and CF7), the backbone-specifi and acetate-specifi antibodies had similar killing activity, and in only 1 sample did dPNAG-specifi antibody have lower opsonic killing activity (figu e 5; CF11). Overall, we consistently found that antibodies specifi to the nonacetylated backbone epitopes of PNAG mediated excellent opsonic killing of S. aureus, whereas, in a minority of serum samples, the dPNAG-specifi antibodies were equivalent to, but not superior to, acetate-specifi antibodies, perhaps because of affinit , fin epitope specificit , or other properties of these less-active dPNAG-specifi antibodies.
DISCUSSION
PNAG is a surface polysaccharide produced by pathogenic staphylococci that has previously been shown to be a target for protective immunity in mice and rabbits. In the present study, we have shown, using serum samples from patients with CF colonized or not colonized with S. aureus, that one particular group of epitopes on PNAG, which is define by a lack of acetate substituents on the amino group of the glucosamine monomer, predominantly bound opsonophagocytic antibodies. Although not all opsonic killing antibodies to bacterial pathogens are also protective, essentially all protective antibodies, particularly those protective against gram-positive organisms, have this in vitro property. Thus, it is likely that any PNAG-specifi immunity will be dependent on antibodies specifi to the epitopes on the dPNAG form of this molecule.
Using whole serum from colonized patients, we have shown Opsonophagocytic killing activity of acetate-specific affinitypurified antibodies (white bars ‫ע‬ SDs) and deacetylated poly N-acetyl glucosamine (dPNAG) (backbone)-specific antibodies (black bars ‫ע‬ SDs). Opsonic killing results obtained using affinity-purified antibodies from 8 different serum samples from patients with cystic fibrosis (CF) colonized with S. aureus are shown. Antibody concentrations in the assay were 5 mg/mL except for sample CF9 dPNAG, which was 1.5 mg/mL. * . P ! .05 that opsonophagocytosis correlates better with dPNAG-specifi IgG antibodies than with PNAG-specifi IgG antibodies. The results of competition ELISAs revealed that PNAG contains both acetate-and backbone-specifi epitopes and that dPNAG contains only the backbone-specifi epitopes. Because of this observation, it is possible to separate the antibody populations and to examine their opsonic activity individually. For 5 of 8 serum samples, antibodies to dPNAG were superior to those against the native PNAG at mediating opsonic killing. For 2 other serum samples, the killing activity of the antibody was comparable, but, importantly, in these serum samples, both populations of antibodies were not as opsonically active as were the dPNAG-specifi antibodies in the other 5 serum samples. In all but 1 instance, PNAG-specifi antibodies and antigen were never superior to dPNAG-specifi antibody and antigen in terms of mediating or inhibiting opsonic killing activity. Overall, antibodies specifi to the backbone of the PNAG molecule will likely be the most useful in preventing and treating staphylococcal disease.
PNAG and dPNAG both contain the backbone epitopes, which may explain why IgG specifi to PNAG in whole serum from the colonized patients did correlate well with the extent of opsonophagocytic killing. In an additional experiment, we found that both purifie PNAG and dPNAG were able to inhibit the opsonophagocytic activity of the serum samples from colonized patients when they were added to the assay (data not shown). This result further demonstrated that the backbonespecifi epitopes are targets for opsonophagocytic antibodies and that PNAG and dPNAG share these epitopes.
The likely importance of dPNAG in protective immunity has been suggested by the recent identificatio of the IcaB protein from S. epidermidis-which is produced from the icaB gene within the ica locus-as an extracellular N-deacetylase that removes N-linked acetates from PNAG [16] . In an S. epidermidis icaB mutant, only fully acetylated PNAG is produced, and this form of the antigen cannot be retained on the cell surface. Only partially dPNAG is cell associated. Because it is likely that IcaB in S. aureus functions identically to IcaB in S. epidermidis, having a reduced-acetate PNAG antigen retained on the cell surface may potentially explain the superiority of dPNAG-specifi antibodies in opsonophagocytic assays. We found that colonized and noncolonized patients had comparable serum levels of antibody to both the native and deacetylated forms of PNAG, which indicates that ELISA measurements did not reflec differences in the functional activities of the antibodies found in colonized patients' serum samples. Attempts to measure a difference in the affinit of the opsonically active versus inactive antibody to dPNAG-including potassium thiocyanate elution, competition ELISAs using both PNAG and dPNAG as competing antigens, and limiting amounts of coating antigen on the ELISA plate-failed to reveal a difference in antibody affinit to PNAG and dPNAG in serum samples from patients with CF. At the moment, the molecular basis for the difference in opsonic activity between the opsonically active and inactive antibodies has not been identified
The most likely reason that noncolonized patients had quan-tifiabl antibody titers to PNAG is previous exposure to this antigen. Because it is now known that not only pathogenic and commensal staphylococci but also Escherichia coli and potentially many other gram-negative pathogens elaborate PNAG [17] , it is clear that there are many possible bacterial sources of exposure to this molecule. Of interest, however, is that noncolonized patients with CF mostly did not develop PNAGspecifi opsonic killing activity, which indicates that natural exposure to this antigen is insufficien to generate these potentially protective antibodies. Antibodies to carbohydrate antigens often mediate protective immunity against many bacterial, and even some fungal, pathogens [18] [19] [20] [21] . However, the importance of different epitopes formed by various chemical substituents in contributing to protective immunity can be quite variable. For example, Oacetyl substituents on the group C Neisseria meningitidis capsule interfered with induction of protective, bactericidal antibodies when used as a conjugate vaccine in humans [22] . In addition, a deacetylated conjugate vaccine using meningococcal C capsular polysaccharide elicited antibodies that were able to kill strains expressing both O-acetylated and deacetylated serogroup C capsule [23] . In contrast, O-acetyl substituents on the S. aureus capsular polysaccharides seem to have no effect on eliciting opsonic antibody that is effective against strains expressing either high or low levels of acetate on the surface capsular polysaccharide antigen [24] . However, opsonic killing and protective polyclonal human antibodies to the Pseudomonas aeruginosa alginate antigen have been shown to be specifi to O-acetyl groups on the mannuronic acid component of the alginate polymer [25] , and a human monoclonal antibody to nonacetylated blocks of mannuronic acid has also been shown to mediate opsonic killing and protection in animal models [26] . Thus, even on the same molecule, several different epitopes can bind opsonic protective antibody.
In conclusion, we have shown that antibodies elicited in response to the PNAG carbohydrate antigen have different functional properties. Antibodies that recognize epitopes present on both highly and poorly acetylated PNAG appear to be superior in mediating phagocyte-dependent opsonic killing, compared with antibodies that require the presence of high levels of acetate to bind to this antigen. The functional antibodies are produced in response to S. aureus colonization in patients with CF, which indicates that a level of exposure beyond commensal encounters with staphylococci or other organisms elaborating PNAG is needed to produce dPNAG-specifi opsonic antibody. In terms of using these data to guide vaccine design, the elicitation of dPNAG-specifi antibodies is technically simple and is likely to be a more facile means of producing a protective response. Indeed, preliminary data have shown that the conjugation of dPNAG to a carrier protein elicits high titers of opsonic and protective antibody in animals, whereas the conjugation of highly acetylated PNAG to the same carrier does not elicit protective antibody [27] . The correlation of the functional activity of antibody responses in infected humans and immunized animals to the different epitopes on PNAG substantiates the pursuit of a vaccine based on eliciting high titers of antibodies to the backbone epitopes on PNAG.
